GLB333 helps to rebuild the damaged tissues, reduces inflammatory conditions and help to regenerate good and healthy muscle and soft tissues.
National Pharma will use the worldwide license to use and market cytokine that is shown to have profound effects on the management of pain due to trauma, wound, and accidents, as well as autoimmune conditions.
National Pharma president Elaine Affleck said they are pleased to obtain the exclusive license to the technology on worldwide basis for GLB333.
"The product that has considerable data already, will be ready for clinical trials Phase I/II in near future," Affleck said.